News

Esbriet is an orally active drug that inhibits the synthesis of TGF-beta, a chemical mediator that controls many cell functions including proliferation and differentiation, and plays a key

Using its proprietary antibody discovery platforms, Humabs is focused on the discovery and development of next-generation fully human monoclonal antibodies targeted at infectious and inflammatory diseases. The technologies

The grant permits Diamyd to develop NTDDS-based drug candidate designed to deliver a neurotrophic factor to nerve cells. Neurotrophic factors are a class of small proteins which promote

Ceplene is administered with interleukin-2 (IL-2) for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first complete remission. The FDA indicated

Ark will work with PsiOxus in providing oncolytic adenoviral material for IV administration in toxicological and Phase I/II clinical studies, using Ark’s suspension based single use system (ATOSUS).

Silence is currently conducting a Phase I trial with Atu027 in patients with advanced solid cancer. Interim data analysis from this trial showed that Atu027 is safe and

Simponi is a human monoclonal antibody that targets and neutralizes excess TNF-alpha, a protein that when overproduced in the body due to chronic inflammatory diseases can cause inflammation

GDUFA requires the FDA to commit to significantly improve and enhance its regulatory activities for the benefit of global generic drug providers and US generic drug users, in

Olesoxime (TRO19622) is the lead compound of the Trophos’ proprietary cholesterol-oxime compound family of mitochondrial pore modulators. The 24-month randomized, parallel group, double-blind, placebo controlled trial will compare